Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NP
Neuropace, Inc. Common Stock
NPCE
Mkt Cap
$420.7M
Volume
89.27K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NP
NPCE
NP
Neuropace, Inc. Common Stock
NPCE
News
·
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight
Mkt Cap
$438.7M
Volume
89.27K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Insider
Filings
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.
GlobeNewswire Inc. · Oct 6, 2026
Why NeuroPace Stock Was Inching Higher on Wednesday
NeuroPace (NPCE) shares rose nearly 1% following the company's earnings release showing strong Q4 2025 performance. The medical device specialist reported revenue of $26.6 million (24% YoY growth) and narrowed its net loss to $2.7 million, beating analyst expectations on both metrics. The company's flagship RNS System epilepsy treatment device drove growth with 26% sales increase. However, 2026 guidance showing modest growth and increased losses tempered investor enthusiasm.
The Motley Fool · Mar 4, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NeuroPace, Inc. (NPCE) announced that its NAUTILUS study did not reach statistical significance for the primary effectiveness endpoint, causing its stock price to fall 28.39%. Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by the company and its officers.
GlobeNewswire Inc. · May 28, 2025
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
NeuroPace, a medical device company focused on epilepsy treatment, announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference.
GlobeNewswire Inc. · Mar 4, 2025
Neuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider
The neuroscience market is rapidly expanding, driven by growing awareness of neurological disorders and advancements in medical research and technology. Key investments from public and private sectors, along with the integration of advanced technologies like Brain-Computer Interfaces, AI, and machine learning, are transforming the neuroscience landscape and creating new market opportunities.
GlobeNewswire Inc. · Nov 11, 2024
Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 7, 2024
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
GlobeNewswire Inc. · Apr 17, 2024
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11.
GlobeNewswire Inc. · Mar 27, 2024
The Latest Analyst Ratings For NeuroPace
Analysts' ratings for NeuroPace (NASDAQ:NPCE) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 2 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for NeuroPace, presenting an average target of $16.33, a high estimate of $22.00, and a low estimate of $12.00. Observing a 48.45% increase, the current average has risen from the previous average price target of $11.00. Analyzing Analyst Ratings: A Detailed Breakdown The standing of NeuroPace among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robbie Marcus JP Morgan Raises Overweight $17.00 $9.00 Ross Osborn Cantor Fitzgerald Raises Overweight $18.00 $16.00 Drew Ranieri Morgan Stanley Raises Equal-Weight $13.00 $9.00 Lawrence Biegelsen Wells Fargo Raises Equal-Weight $16.00 $9.00 Mike Kratky Leerink Partners Announces Outperform $22.00 - Frank Takkinen Lake Street Maintains Buy $12.00 $12.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com
Benzinga · Mar 12, 2024
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 --
GlobeNewswire Inc. · Mar 5, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
NP
NPCE
Neuropace, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
NPCE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any NPCE yet.
Related Tickers
Earnings